Siffrorna i kvartalet visar på volatiliteten i affären Omsättningen i kvartalet uppgick till 45,4 mk...
Redeye sees a softer Q1 report from Hanza than expected.
Agencyutvecklingen överskuggar stark utveckling inom (D)OOH och AdTech Intäkterna för Q1 minskade me...
Taaleri reported Q1 EBIT of EUR 9.6m, coming well in line with LSEG Data & Analytics consensus at EU...
Redeye updates its estimates and valuation after reviewing Tessin's Q1 report, which showed lower sa...
Redeye maintains its optimistic outlook post the Q1 2024 report despite slightly lower sales and pro...
Redeye returns with a positive view on the back of Bredband2’s Q1 2024 report posting solid growth a...
Redeye comments on Alligator Bioscience's Q1 report, including the sub-optimal funding situation aft...
EBITA SEK 238m (+22% vs. ABGSCe, +21% vs. FactSet cons) We expect cons.
Permit for Viscaria granted, a major milestone Permit allows for 3.
Redeye comments on Salénterprise’s mandatory bid of all shares in NeoDynamics for SEK1.
Redeye comments on Tessin’s Q1 results, which showed lower loan volumes than expected, negatively im...
Redeye continues to be positive to Bredband2 following a solid Q1 report, where growth initiatives i...
Redeye leaves a short comment following Lipum’s announcement of a loan commitment of SEK20m with Fle...
Analyst Group has entered into an agreement with ODI Pharma on commissioned research, including e.
CapMan’s Q1 clearly beat our estimates driven by carried interest and positive fair value changes, b...
Vaisala’s Q1/24 was soft as expected yet delivered slight earnings beat vs.
Setanaxib delivers promising results when used together with Keytruda in a tumour type, where Setana...
Decelerating org. growth but strong cash flow '24e-'26e adj.
IRL757 Ph 1 received regulatory approval SAD/MAD study to finish by YE'24 Results expected in Q1'25e...
